The attenuated bacille Calmette-Guérin (BCG) vaccine is administered to prevent tuberculosis. Complications of vaccination are uncommon. We report a new case of disseminated BCG disease and review 27 additional cases identified from a review of ú5,000 reports published between 1980 and 1996. Twenty-four of the 28 total cases were associated with an immune deficiency, including nine cases of AIDS. Seventy-one percent of the cases occurred in children younger than 2 years old. Sixty-eight percent of the patients were male. About one-half of the patients were vaccinated in a developed nation, but 85% of the cases were reported from a developed nation. Response to therapy was poor, with an overall mortality rate of 71%. We made two new observations. Disseminated BCG disease has historically been a disease of infants, but cases now occur in adults and older children coinfected with human immunodeficiency virus. Cases also occur after revaccination of individuals who were anergic following the initial administration of BCG vaccine. Disseminated BCG disease is an uncommon but devastating complication of vaccination that should be considered in the appropriate clinical setting. Immunocompromised infants and patients with late-stage AIDS are at greatest risk and respond poorly to standard therapies.
The original BCG strain of Mycobacterium bovis was deand fever; her family history was unavailable. Her medical rived from multiple passages of wild-type M. bovis [1] . BCG history revealed that she had had frequent illnesses since birth, vaccine is administered worldwide to prevent tuberculosis and including bronchiolitis, pneumonia, and chronic bloody diaris considered to have an excellent safety profile. However, rhea. Immunization over the right deltoid muscle with Moreau complications do occur, including abscesses at the site of inocu-BCG vaccine (Fundao Ataufo de Paiva, Rio de Janeiro) at 10 lation and localized lesions such as osteitis [2] . The most seridays of age had resulted in a nonhealing ulcer. One month ous complication is disseminated disease. before admission, the child developed dyspnea, productive We report a new case of disseminated BCG disease in an cough, abdominal distention, increased diarrhea, fever, and an infant with immunodeficiency. We also present a working enlarging right axillary mass. definition of disseminated BCG disease, which we use to reAt the time of admission, the child had a temperature of view the literature on disseminated BCG disease resulting from 38.9ЊC and labored breathing. She appeared pale and listless vaccination. We identified 28 definite [3 -21] and nine probable and had moderate thrush. The site of BCG vaccination was [22 -28] cases reported from 1980 through 1995, a period that enlarged, erythematous, and weeping. A soft, mobile right axiloverlaps minimally with those of a previous retrospective relary lymph node (5 cm in size) was present. There were diffuse view [29] and a prior prospective study [30] . The topic of rhonchi. Abdominal examination showed distention, hepatodisseminated BCG disease warrants reevaluation, given imsplenomegaly, and a firm, mobile 3-cm mass in the epigastrium. proved diagnostic methods, an expanded concept of disseminLaboratory studies at the time of admission revealed a WBC ated mycobacterial disease, and the progression of the AIDS count of 12,700/mm 3 (10% lymphocytes), hematocrit of 17%, epidemic.
and platelet count of 118,000/mm 3 . Testing for antibody to HIV by ELISA was negative twice. Ultrasonography confirmed Case Report the presence of a heterogeneous abdominal mass measuring An 8-month-old girl presented to a pediatric hospital in Vito-3.0 1 6.2 cm. ria, Brazil, with a 3-week history of bloody diarrhea, cough, A tuberculin test was nonreactive, and microscopic examinations of sputum and gastric aspirates were negative for acidfast bacilli. However, biopsies of the axillary and abdominal CID 1997; 24 (June) carinii infection, esophageal candidiasis, and diffuse lymphaccording to the working definition shown in table 2. The rationale for this definition is presented under Discussion. adenopathy. Well-developed granulomas and many acid-fast bacilli were found in both the liver and spleen.
Results
Case. The isolate from the abdominal mass in our patient Methods was identified as BCG by the methods described above Culture and identification. The biopsy sample from the [31 -33] . The isolate was susceptible to isoniazid, rifampin, abdominal mass was cultured, and the isolate was identified to streptomycin, and ethambutol and was resistant to pyrazinthe species level by growth inhibition by p-nitroacetylaminohyamide. Our case was classified as definite disseminated disease droxypropiophenone and thiophene-2-carboxylic acid hydraon the basis of evidence of infection at three extraregional zide, nitrate reduction, and niacin production. Drug susceptisites (abdominal lymph node, liver, and spleen) and a systemic bility testing was performed by means of the BACTEC System syndrome consistent with mycobacterial disease (fever, weight (Becton Dickinson, Sparks, MD). Two additional methods were loss, anemia, and death). used to confirm the identity of the isolate as BCG. A specific Literature review and case classification. We reviewed genomic region containing the major polymorphic tandem re-ú5,000 reports and identified 27 additional cases of definite peat (MPTR) was amplified by PCR analysis, and restriction disseminated BCG disease that were reported from 1980 enzyme analysis (REA) was carried out according to the pubthrough 1995; these cases are summarized in Sites of dissemination were established by culture or histoHealth Sciences Literature of the Pan-American Health Organilogical demonstration of acid-fast bacilli. The most common zation Library with use of a similar search strategy. These sites of dissemination were lymph nodes, which were identified databases include literature published since 1985. Reference in 24 of 28 cases. Blood or bone marrow was positive for BCG lists of case reports, trials, and reviews were also examined in nine cases. Other common sites of dissemination were the for relevant articles.
lung, liver, spleen, skin, and bone. Cases resulting from any mechanism other than vaccination
The most commonly reported symptoms in the definite cases (e.g., intravesical instillation of BCG for the treatment of bladof disseminated BCG disease were fever, lymphadenopathy, der cancer) were excluded from analysis. Cases identified by and weight loss. Failure to thrive and hepatosplenomegaly the literature searches were classified according to table 1.
were also common. Reporting of symptoms was incomplete, Each potential case of disseminated disease was then evaluated and associating symptoms with disseminated BCG disease was sometimes difficult because of comorbid illnesses. Most therapeutic regimens included at least isoniazid and infected patients who are immunized with BCG vaccine are at increased risk. There has even been one case of apparent reactivation of BCG disease and symptomatic dissemination that occurred in a patient with AIDS 30 years after vaccination was often identified in the lymph nodes, and the mortality rate (case 4); this case suggests that HIV-infected patients can dewas high despite aggressive antimicrobial therapy.
velop complications of BCG vaccination even if they are immunized with BCG vaccine before the acquisition of HIV infection.
Discussion
Not all cases of disseminated BCG disease in HIV-infected patients are reported. BCG vaccination is currently used where Background. The original BCG strain was derived from M. bovis and was first used as a tuberculosis vaccine in 1921.
HIV infection is epidemic but testing for HIV infection is not routinely done. In the developing nations, lack of resources Over 3 billion doses of BCG vaccine have been given since 1948, and it has been considered to be safe [1] . However, makes the routine and accurate identification of pathogens in patients with AIDS difficult. Disseminated BCG disease may complications do occur. Lotte et al. [29] reviewed ú1,000 reports and found that 10,000 complications of BCG vaccinabe misdiagnosed as infection due to Mycobacterium tuberculosis or M. bovis. The relative paucity of cases in the developing tion were reported between 1921 and 1982. Their retrospective review identified 60 cases of dissemination for which the morworld that were identified by our review and that of Lotte et al. [29] may reflect incomplete reporting or reporting in sources tality rate was 50%. In a later prospective survey of complications of BCG vaccination [30] , the same researchers studied not accessed by our search strategies. There have been prospective studies identifying the risk of all infants vaccinated between 1979 and 1981 in six European countries. The 5.5 million infants who were vaccinated were disseminated disease in asymptomatic HIV-infected patients [4, 43 -47] . One recent study [48] enrolled 155 adults with followed up through 1983 by means of a questionnaire. The estimated incidence of disseminated disease was 2 cases per 1 AIDS who had received BCG vaccination as children. Blood specimens for mycobacterial cultures were obtained at study million vaccinated children, and the mortality rate was 80%.
BCG disease and immunodeficiencies. Serious complicaentry and at 6 months. None of the cultures of specimens from these patients were positive for BCG. Most studies are tions of BCG vaccination, such as generalized lymphadenitis [34] and disseminated disease [35] , do occur in normal hosts, small with inadequate follow-up; therefore, the actual risk to asymptomatic HIV-infected patients remains poorly characbut these complications are exceptional. In the retrospective review of disseminated BCG disease by Lotte et al. [29] , celluterized.
Identification of BCG.
Mycobacterial isolates are frelar immunodeficiency was identified as the chief risk factor for fatal outcome. Of the 60 total patients who were identified, 31 quently identified in clinical microbiology laboratories to the level of the M. tuberculosis complex, which includes M. tuberdied. All patients who died had a ''definite'' or ''highly probable'' cellular immunodeficiency. NOTE. CGD Å chronic granulomatous disease; Clof Å clofazimine; CMI Å cell-mediated immune defect; Cyse Å cycloserine; D Å distant; Eth Å ethambutol; Ethi Å ethionamide; HM Å hepatomegaly; HSM Å hepatosplenomegaly; INH Å isoniazid; LAD Å lymphadenopathy; LN Å lymph node; NR Å not reported; PAS Å p-aminosalicylic acid; PR Å present report; PZA Å pyrazinamide; R Å regional; Rif Å rifampin; SCID Å severe combined immunodeficiency; SOB Å shortness of breath; Stm Å streptomycin.
nation of biochemical and growth features can strongly suggest well as specialized and expensive equipment. IS1081 fingerprinting is more laborious, requiring careful isolation of DNA that an isolate is BCG, but none of these features are definitive [49, 50] .
from a large bacterial culture followed by Southern blot hybridization with a specific probe. This technique is generally not There are four validated methods for the definitive identification of BCG. These four methods are phage typing [51] , available to clinical microbiology laboratories. Amplification of MPTR by PCR and REA only requires a small specimen HPLC [52] , restriction fragment length polymorphism analysis with use of the insertion element IS1081 as a probe (i.e., IS1081 from a clinical isolate, has been applied to heat-killed cultures [31] , and may be directly applicable to smear-positive clinical fingerprinting) [53] , and amplification of a specific region containing the MPTR by PCR followed by REA [31] . Each of specimens, as has been reported for other PCR-based methods for strain differentiation [54] . these methods has advantages and disadvantages. Phage typing is laborious and not widely available. HPLC is rapid and easy
Rationale for the working definition of disseminated BCG disease. The working definition of disseminated BCG disease to perform, but it requires a fresh isolate on proper medium as / 9c2f$$ju20
05-06-97 20:09:15 cida UC: CID NOTE. Amik Å amikacin; CGD Å chronic granulomatous disease; Clof Å clofazimine; CMI Å cell-mediated immune defect; D Å distant; Eth Å ethambutol; Ethi Å ethionamide; HSM Å hepatosplenomegaly; INH Å isoniazid; LAD Å lymphadenopathy; LN Å lymph node; NR Å not reported; PZA Å pyrazinamide; R Å regional; Rif Å rifampin; SCID Å severe combined immunodeficiency; SM Å splenomegaly; Stm Å streptomycin.
(table 2) requires the following: a culture positive for BCG vaccination [60] . In 1956, Gormsen [61] performed autopsies on BCG-vaccinated infants and children who died of unrelated (the identification of which has been confirmed by biochemical methods at least); demonstration of dissemination by either a causes; histological examination of tissues demonstrated granulomas in many distant organs, including liver, lungs, spleen, positive blood or bone marrow culture or evidence of infection at two or more anatomic sites beyond the region of vaccination; and kidneys. Organisms were found up to 3 years after vaccination without evidence of clinical disease. This work was effecand signs and symptoms consistent with mycobacterial disease. This working definition was developed before our literature tively reproduced by Trevenen and Pagtakhan [62] in 1982.
Treatment of disseminated BCG disease.
There is pessisearch as a tool to identify only definite cases. We used the literature on disseminated Mycobacterium avium complex dismism in the historic literature regarding the treatment of disseminated BCG disease in immunocompromised hosts. In ease [55] and other disseminated mycobacterial diseases [56] to develop the working definition of disseminated BCG disease.
1972, Sicevic [63] wrote that ''it is generally known that antitubercular drugs have no effect on the treatment of generalized Some researchers have used the terms disseminated or generalized to refer to any locus of infection beyond the region of BCG tuberculosis in immunodeficient children.'' In 1977, Genin et al. [64] referred to the inevitable progression to death vaccination. We believe that there are important distinctions between extraregional localized disease (e.g., isolated osteitis within 6 months in immunocompromised patients with generalized disease in spite of antimicrobial therapy. or lymphadenitis) and disseminated disease involving multiple organ systems. For example, disseminated BCG disease occurs There is little published information about regimens that are useful in the treatment of disseminated BCG disease that occurs almost exclusively in immunocompromised hosts, is frequently associated with a negative tuberculin test, is not associated with after vaccination. However, there are therapeutic precedents established for other types of infection caused by BCG. Therhistological findings of well-formed granulomas [57] , responds poorly to therapy, and is frequently fatal. In contrast, generalapy for disseminated disease following intravesical instillation of BCG should include isoniazid, rifampin, and a corticosteroid ized BCG lymphadenitis occurs in immunocompetent hosts (for whom results of tuberculin tests are normal), provokes a [65, 66] . Isoniazid, rifampin, and erythromycin have been used in the treatment of suppurative lymphadenitis at the site of typical histological response [58, 59] , and can sometimes resolve without therapy [34] .
BCG vaccination [67, 68] . Experience with treatment of infection due to non -BCG The third requirement for our working definition is a systemic syndrome consistent with mycobacterial disease. This strains of M. bovis is limited, but this therapy is another obvious model for disseminated BCG disease. Ten patients with requirement is intended to distinguish disseminated BCG disease from the asymptomatic dissemination of BCG that occurs M. bovis infection in a Spanish review [69] all received therapy with isoniazid, rifampin, and ethambutol. Nine patients were after vaccination of infants with an intact immune system. In fact, dissemination of BCG is a normal sequela of BCG cured and had no relapses, and one patient died of other causes.
/ 9c2f$$ju20 05-06-97 20:09:15 cida UC: CID
In another retrospective review [70] , most M. bovis isolates The American Academy of Pediatrics [84] recommends that a child who receives BCG vaccination but does not have a from 73 patients were sensitive to first-line antituberculous drugs (except pyrazinamide, to which M. bovis is uniformly positive reaction to the tuberculin test be revaccinated. The benefit of this second BCG vaccination for prevention of tuberresistant), and nearly all patients responded to therapy.
The antimycobacterial regimens used to treat patients whose culosis is not established, but our review indicates that there are risks associated with this practice. Patients with severe cases were identified in our review are listed in tables 3 and 4. Isoniazid, rifampin, ethambutol, and streptomycin were most immunodeficiencies (including AIDS and severe combined immunodeficiency) are often anergic and would be selected for commonly used. It is striking that ú70% of patients died even when their cases were aggressively managed. Plausible explarepeated vaccination by this policy. Three cases of disseminated BCG disease (nos. 24, 30, and 36) developed after revaccinations for this high mortality rate include associated immunodeficiencies, delay in diagnosis or treatment (case 3), initial nation because of a negative tuberculin test. Case reporting. Confirmed or suspected cases of dissemintreatment with pyrazinamide to which BCG is uniformly resistant (cases 18 and 22) , and the emergence of resistance to ated BCG disease should be reported in the medical literature and to the appropriate authorities. Because disseminated BCG therapy (case 24) [63] . The high mortality rate may be a result of reporting bias.
disease is caused by an adverse drug reaction, cases should be reported to vaccine manufacturers (in the United States, Experience in the treatment of patients with AIDS and other mycobacterial diseases may provide principles for the treatment Organon Teknika, Durham, NC [800-842-3220]) and the Vaccine Adverse Event Reporting System (800-822-7967). The of immunocompromised patients with disseminated BCG disease. Poor drug absorption, drug interactions, and frequent adcorresponding author of this article (R.F.) would be pleased to collaborate in the definite identification of possible BCG verse drug reactions have been observed to complicate therapy for mycobacterial infections in patients with AIDS [71 -74] .
isolates. Prolonged therapy is recommended for patients with AIDS and M. tuberculosis [75] or M. avium complex infections [76] . vaccine has recently been published [77] . Virtually nothing is known about the efficacy of BCG vaccine for infants with
Note Added in Proof
HIV infection. However, HIV infection greatly increases the incidence of tuberculosis, so even a small degree of efficacy A new method of BCG identification was applied to cultures would have a major impact [78] . In addition to the effects on that were killed using ethanol and shipped without hazard at room tuberculosis, BCG vaccine may also prevent other mycobactetemperature [85] . This method is available to clinicians worldwide rial diseases, including cervical lymphadenitis due to atypical for confirmation of BCG complications. mycobacteria [79, 80] and Hansen's disease [81] .
The risks associated with BCG vaccination include local
